Bridgewater Associates LP Sells 221,691 Shares of DexCom, Inc. (NASDAQ:DXCM)

Bridgewater Associates LP decreased its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 69.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 97,938 shares of the medical device company's stock after selling 221,691 shares during the period. Bridgewater Associates LP's holdings in DexCom were worth $7,617,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Versant Capital Management Inc acquired a new stake in DexCom in the fourth quarter worth $25,000. Private Trust Co. NA increased its holdings in shares of DexCom by 266.3% in the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock worth $26,000 after acquiring an additional 245 shares during the period. TD Private Client Wealth LLC lifted its position in DexCom by 62.8% in the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after purchasing an additional 167 shares during the last quarter. Larson Financial Group LLC boosted its stake in DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after purchasing an additional 137 shares during the period. Finally, Heck Capital Advisors LLC acquired a new stake in shares of DexCom in the fourth quarter valued at approximately $38,000. Institutional investors and hedge funds own 97.75% of the company's stock.

Wall Street Analyst Weigh In

DXCM has been the subject of a number of recent analyst reports. Morgan Stanley increased their price objective on DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a report on Friday, February 14th. Wells Fargo & Company reissued an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Baird R W raised shares of DexCom from a "hold" rating to a "strong-buy" rating in a report on Thursday, January 16th. Robert W. Baird upgraded shares of DexCom from a "neutral" rating to an "outperform" rating and increased their target price for the company from $86.00 to $104.00 in a research report on Thursday, January 16th. Finally, Canaccord Genuity Group boosted their price target on shares of DexCom from $99.00 to $103.00 and gave the stock a "buy" rating in a research report on Friday, February 14th. Five analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $99.00.

Insider Buying and Selling at DexCom

In related news, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the sale, the chief executive officer now directly owns 319,037 shares in the company, valued at approximately $27,727,505.67. This trade represents a 9.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Jacob Steven Leach sold 2,634 shares of the company's stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the transaction, the chief operating officer now directly owns 268,644 shares in the company, valued at approximately $23,347,850.04. The trade was a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 105,009 shares of company stock valued at $8,044,178 in the last 90 days. 0.32% of the stock is currently owned by corporate insiders.

DexCom Price Performance

Shares of NASDAQ DXCM traded down $0.14 during mid-day trading on Friday, reaching $68.59. The company had a trading volume of 3,702,730 shares, compared to its average volume of 4,222,362. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $139.24. The stock has a market cap of $26.90 billion, a PE ratio of 47.97, a P/E/G ratio of 2.30 and a beta of 1.50. The company has a 50-day moving average price of $74.98 and a two-hundred day moving average price of $76.67.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, equities analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.